Journal article
The London position statement of the World Congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response
GR D'Haens, R Panaccione, PDR Higgins, S Vermeire, M Gassull, Y Chowers, SB Hanauer, H Herfarth, DW Hommes, M Kamm, R Löfberg, A Quary, B Sands, A Sood, G Watermayer, B Lashner, M Lémann, S Plevy, W Reinisch, S Schreiber Show all
American Journal of Gastroenterology | Published : 2011
DOI: 10.1038/ajg.2010.392
Abstract
The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other biological agents (adalimumab (ADA), certolizumab pegol (CZP), and natalizumab (NAT)) appear to have similar benefits in CD. Steroid-refractory, steroid-dependent, or complex fistulizing CD are indication..
View full abstractGrants
Funding Acknowledgements
We are grateful to Nicole Eichinger and Sonja Rosensweig, secretariat of the European Crohn's and Colitis Organisation, for their help with the logistics of the meetings and to Christine Mazziotta for technical assistance in preparing the manuscript. Financial support for administration was provided by a standard grant for Position Statements from the World Congress of Gastroenterology. The Pharmaceutical Industry was excluded from all stages of the process.